Abstract
Although the 5-HT5 receptor subfamily was discovered more than 15 years ago, it is unambiguously the least known 5-HT receptor subtype. The Gi/G0-mediated signal transduction and its intensive presence in raphe and other brainstem and pons nuclei suggest mechanisms similar to those of 5-HT1 receptors, the ligands of which are already applied in the treatment of e.g. anxiety and migraine. In addition, a unique coupling and inhibition of adenosine diphosphate-ribosyl cyclase have also been described. High concentrations of 5-HT5 receptor in other key regions including, e.g. locus coeruleus, nucleus of the solitary tract, arcuate and suprachiasmatic nuclei of the hypothalamus indicate a wide range of physiological effects, thus its ligands are potential drug candidates in various areas, e.g. anxiety, sleep, incontinence, food intake, learning and memory, pain or chemoreception pathways. These findings have motivated several institutes and pharmaceutical companies to participate in the research of this field. Despite extensive research, no selective agonist and only two selective antagonists have been identified until now. Beyond these compounds, the present review provides a complete overview on all other published 5-HT5A receptor ligands as well as on the structure, function, distribution, genetics and possible therapeutic applications of this receptor.
Keywords: Serotonin, 5-HT5, 5-HT5A, 5-HT autoreceptor, neuronal hyperpolarization, drug target, anxiety, sleep, incontinence, food intake, learning and memory, pain
Current Topics in Medicinal Chemistry
Title: Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Volume: 10 Issue: 5
Author(s): Balazs Volk, Bence J. Nagy, Szilvia Vas, Diana Kostyalik, Gyula Simig and Gyorgy Bagdy
Affiliation:
Keywords: Serotonin, 5-HT5, 5-HT5A, 5-HT autoreceptor, neuronal hyperpolarization, drug target, anxiety, sleep, incontinence, food intake, learning and memory, pain
Abstract: Although the 5-HT5 receptor subfamily was discovered more than 15 years ago, it is unambiguously the least known 5-HT receptor subtype. The Gi/G0-mediated signal transduction and its intensive presence in raphe and other brainstem and pons nuclei suggest mechanisms similar to those of 5-HT1 receptors, the ligands of which are already applied in the treatment of e.g. anxiety and migraine. In addition, a unique coupling and inhibition of adenosine diphosphate-ribosyl cyclase have also been described. High concentrations of 5-HT5 receptor in other key regions including, e.g. locus coeruleus, nucleus of the solitary tract, arcuate and suprachiasmatic nuclei of the hypothalamus indicate a wide range of physiological effects, thus its ligands are potential drug candidates in various areas, e.g. anxiety, sleep, incontinence, food intake, learning and memory, pain or chemoreception pathways. These findings have motivated several institutes and pharmaceutical companies to participate in the research of this field. Despite extensive research, no selective agonist and only two selective antagonists have been identified until now. Beyond these compounds, the present review provides a complete overview on all other published 5-HT5A receptor ligands as well as on the structure, function, distribution, genetics and possible therapeutic applications of this receptor.
Export Options
About this article
Cite this article as:
Volk Balazs, Nagy Bence J., Vas Szilvia, Kostyalik Diana, Simig Gyula and Bagdy Gyorgy, Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential, Current Topics in Medicinal Chemistry 2010; 10 (5) . https://dx.doi.org/10.2174/156802610791111588
DOI https://dx.doi.org/10.2174/156802610791111588 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting G-Quadruplex DNA for Cancer Chemotherapy
Current Drug Discovery Technologies Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Cellular Photodynamic Toxicity of Hematoporphyrin in Various Nanocarrier Systems
Current Nanoscience Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews cAMP-Mediated Regulation of CYP Enzymes and Its Application in Chemotherapy
Drug Metabolism Letters The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Predicting Hub Genes of Glioblastomas Based on a Support Vector Machine Combined with CFS Algorithms
Current Bioinformatics